Authors : Dwaipayan Hor; Rajendra Chouksey; Soumen Dey; Priya Barman; Abul Hasnat

Volume/Issue : Volume 10 - 2025, Issue 11 - November

Google Scholar : https://tinyurl.com/3ft8jdrw

Scribd : https://tinyurl.com/hzzkr8dy

DOI : https://doi.org/10.38124/ijisrt/25nov019

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Multidrug-resistant (MDR) bacterial infections are becoming more common, which is a serious global health concern that calls for innovative antimicrobial approaches that go beyond traditional antibiotic treatments. In order to improve antibacterial efficacy, this review carefully investigates hybrid nano-bio platforms that combine probiotic-derived metabolites with nanoscale delivery technologies in a synergistic manner. Despite having natural antibacterial, antibiofilm, and immunomodulatory properties, probiotic metabolites such as bacteriocins, biosurfactants, organic acids, and reuterin are clinically limited because of their poor stability and lack of targeted administration. By enhancing bioavailability, stability, and permitting controlled, stimuli-responsive release, encapsulation within nanocarriers such polymeric nanoparticles, liposomes, solid lipid nanoparticles, and metallic nanostructures overcomes these difficulties. These hybrid systems restore antibiotic sensitivity and increase pathogen clearance by acting through a variety of antibacterial mechanisms, such as membrane rupture, efflux pump inhibition, biofilm penetration, and immunological modulation. Stimuli-responsive designs maximise therapeutic specificity while reducing off-target toxicity by enabling precise drug release in response to microenvironmental cues such as pH changes or oxidative stress. Translational obstacles still exist despite encouraging preclinical studies showing strong and long-lasting antibacterial activities with excellent biocompatibility characteristics. These include issues with thorough safety evaluations, regulatory classification, and scalable production. The development of adaptive, multifunctional, and safe next-generation antimicrobials that can successfully combat MDR pathogens and stop the global antibiotic resistance crisis is made possible by the interdisciplinary integration of microbial biotechnology and nanomedicine, which is embodied in hybrid nano-bio platforms.

Keywords : Hybrid Nanocarriers, Probiotic Metabolites, Antimicrobial Resistance, Biofilm Inhibition, Bacteriocins, Nanomedicine.

References :

1. Mba IE, Nweze EI. Nanoparticles as therapeutic options for treating multidrug-resistant bacteria: research progress, challenges, and prospects. World Journal of Microbiology and Biotechnology. 2021 Jun;37(6):108.
2. Talebi Bezmin Abadi A, Rizvanov AA, Haertlé T, Blatt NL. World Health Organization report: current crisis of antibiotic resistance. BioNanoScience. 2019 Dec;9(4):778-88.
3. Machado A, Zamora-Mendoza L, Alexis F, Álvarez-Suarez JM. Use of plant extracts, bee-derived products, and probiotic-related applications to fight multidrug-resistant pathogens in the post-antibiotic era. Future Pharmacology. 2023 Jul 4;3(3):535-67.
4. Abouelela ME, Helmy YA. Next-generation probiotics as novel therapeutics for improving human health: current trends and future perspectives. Microorganisms. 2024 Feb 20;12(3):430.
5. Chugh B, Kamal-Eldin A. Bioactive compounds produced by probiotics in food products. Current opinion in food science. 2020 Apr 1;32:76-82.
6. Singh AP, Biswas A, Shukla A, Maiti P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal transduction and targeted therapy. 2019 Aug 30;4(1):33.
7. Saini P, Chakraborty T, Jain A, Saini V “Taste masking of Bitter Drug in Suspension: An overview” International Journal of Pharmaceutical Sciences Letters 2013 Vol. 3 (4) Page 229-237.
8. Bazana MT, Codevilla CF, de Menezes CR. Nanoencapsulation of bioactive compounds: Challenges and perspectives. Current opinion in food science. 2019 Apr 1;26:47-56.
9. Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert opinion on drug delivery. 2021 Feb 1;18(2):205-27.
10. Kumar A, Goyal K, Ullah SN, Jindal S. Stimuli responsive nanotechnological advancements in infectious disorders. InNanostructured Drug Delivery Systems in Infectious Disease Treatment 2024 Jan 1 (pp. 83-101). Academic Press.
11. Rawat N, Ahmad N, Raturi P, Singhvi N, Sahai N, Kothiyal P. Nanobiomaterials: exploring mechanistic roles in combating microbial infections and cancer. Discover Nano. 2023 Dec 20;18(1):158.
12. Yadav A, Thakur P, Thakur A, Suhag D. Challenges in Scaling Nanobiology for Clinical Use. InAdvancements in Nanobiology 2025 Mar 25 (pp. 303-317). CRC Press.
13. Chakraborty T, Saini V, Singh G , Govila D and Pandurangan A “Causes and Management of Major Microbial Infections in Upper Sensory Organs of the Body” International Journal of Pharmaceutical Sciences Review and Research, 2018, 48(1):43-51.
14. Rajkhowa S, Hussain SZ, Agarwal M, Zaheen A, Al-Hussain SA, Zaki ME. Advancing Antibiotic-Resistant Microbe Combat: Nanocarrier-Based Systems in Combination Therapy Targeting Quorum Sensing. Pharmaceutics. 2024 Sep 3;16(9):1160.
15. Chen A, Gong Y, Wu S, Du Y, Liu Z, Jiang Y, Li J, Miao YB. Navigating a challenging path: precision disease treatment with tailored oral nano-armor-probiotics. Journal of Nanobiotechnology. 2025 Feb 1;23(1):72.
16. Shahcheraghi N, Golchin H, Sadri Z, Tabari Y, Borhanifar F, Makani S. Nano-biotechnology, an applicable approach for sustainable future. 3 Biotech. 2022 Mar;12(3):65.
17. Rathore R, Yadav A. Bio-nanotechnology in Cancer Research. InAdvancements in Nanobiology 2025 Mar 25 (pp. 215-234). CRC Press.
18. Thapa S, Li H, OHair J, Bhatti S, Chen FC, Nasr KA, Johnson T, Zhou S. Biochemical characteristics of microbial enzymes and their significance from industrial perspectives. Molecular biotechnology. 2019 Aug 1;61(8):579-601.
19. Percival SL, McCarty S, Hunt JA, Woods EJ. The effects of pH on wound healing, biofilms, and antimicrobial efficacy. Wound repair and regeneration. 2014 Mar;22(2):174-86.
20. Bernardes BG, Veiga A, Barros J, García-González CA, Oliveira AL. Sustainable silk-based particulate systems for the controlled release of pharmaceuticals and bioactive agents in wound healing and skin regeneration. International Journal of Molecular Sciences. 2024 Mar 8;25(6):3133.
21. Li X, Peng X, Zoulikha M, Boafo GF, Magar KT, Ju Y, He W. Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduction and Targeted Therapy. 2024 Jan 1;9(1):1.
22. Mallick MA, Chakraborty T et.al “Schematic diagrammatic preparation methods of polymeric nanoparticles for biomedical applications in recent and future prospects” European Chemical Bulletin , 2023,12(10):1721-1733
23. Monika K, Malik T, Gehlot R, Rekha K, Kumari A, Sindhu R, Rohilla P. Antimicrobial property of probiotics. Environment Conservation Journal. 2021 Mar 8;22(SE):33-48.
24. Basu Thakur P, Long AR, Nelson BJ, Kumar R, Rosenberg AF, Gray MJ. Complex responses to hydrogen peroxide and hypochlorous acid by the probiotic bacterium Lactobacillus reuteri. Msystems. 2019 Oct 29;4(5):10-128.
25. Thakur PB, Long AR, Nelson BJ, Kumar R, Rosenberg AF, Gray MJ. Complex responses to hydrogen peroxide and hypochlorous acid by the probiotic bacterium Lactobacillus reuteri. MSystems. 2019 Sep 3;4(5):e00453-19.
26. Umekar M, Chaudhary AA, Manghani M, Shidhaye S, Khajone P, Mahore J, Rudayni HA, Trivedi R. Probiotics in Nanotechnology-Driven Wound Healing: From Mechanistic Insight to Clinical Promise. Pharmaceutics. 2025 Jun 21;17(7):805.
27. Srivastava P, Kim KS. Membrane vesicles derived from gut microbiota and probiotics: cutting-edge therapeutic approaches for multidrug-resistant superbugs linked to neurological anomalies. Pharmaceutics. 2022 Nov 3;14(11):2370.
28. Hetta HF, Ramadan YN, Al-Harbi AI, A. Ahmed E, Battah B, Abd Ellah NH, Zanetti S, Donadu MG. Nanotechnology as a promising approach to combat multidrug resistant bacteria: a comprehensive review and future perspectives. Biomedicines. 2023 Jan 31;11(2):413.
29. Kalia P, Thakur P, Kumar R. Advancing Precision Therapeutics Integrating Microbiota Biomarkers and Nanotechnology for Targeted Drug Delivery: Insights from Case Studies. Microbiota Profiling for Precision Medicine: Biomarker-Targeted Drug Delivery Strategies. 2025 Oct 20:239-80.
30. Chakraborty T, Natasha, Saini V, Ruby “Formulation and evaluation of controlled release floating tablets of cefixime using hydrophilic polymers” International Research Journal of Pharmacy, 2019, 10 (1): 171-175.
31. Benedetto Tiz D, Kikelj D, Zidar N. Overcoming problems of poor drug penetration into bacteria: challenges and strategies for medicinal chemists. Expert Opinion on Drug Discovery. 2018 Jun 3;13(6):497-507.
32. Tiwari AK, Pandey PC, Gupta MK, Narayan RJ. Nano–bio interaction and antibacterial mechanism of engineered metal nanoparticles: fundamentals and current understanding. Journal of Cluster Science. 2025 Feb;36(1):5.
33. Barbinta-Patrascu ME, Badea N, Pirvu C, Bacalum M, Ungureanu C, Nadejde PL, Ion C, Rau I. Multifunctional soft hybrid bio-platforms based on nano-silver and natural compounds. Materials Science and Engineering: C. 2016 Dec 1;69:922-32.
34. Habeeb M, Vengateswaran HT, Kumbhar ST, You HW, Asane GS, Aher KB. Nano–bio interactions: understanding their dynamic connections. InTheranostics Nanomaterials in Drug Delivery 2025 Jan 1 (pp. 11-25). Academic Press.
35. Wang Y, Zhang X, Yue H. Two-dimensional nanomaterials induced nano-bio interfacial effects and biomedical applications in cancer treatment. Journal of Nanobiotechnology. 2024 Feb 18;22(1):67.
36. Chakraborty T, Saini V, Narwal P, Gupta S “Formulation and evaluation of both stomach and Intestine drug delivery system from unit solid dosage tablet formulation” World Journal of Pharmaceutical Research, 2015:4(10): 1377-1392.
37. Barbinta-Patrascu ME, Badea N, Pirvu C, Bacalum M, Ungureanu C, Nadejde PL, Ion C, Rau I. Multifunctional soft hybrid bio-platforms based on nano-silver and natural compounds. Materials Science and Engineering: C. 2016 Dec 1;69:922-32.
38. Mahyad B, Janfaza S, Hosseini ES. Bio-nano hybrid materials based on bacteriorhodopsin: potential applications and future strategies. Advances in colloid and interface science. 2015 Nov 1;225:194-202.
39. Ivanova K, Ivanova A, Hoyo J, Pérez-Rafael S, Tzanov T. Nano-formulation endows quorum quenching enzyme-antibiotic hybrids with improved antibacterial and antibiofilm activities against Pseudomonas aeruginosa. International journal of molecular sciences. 2022 Jul 11;23(14):7632.
40. Lipsi K, Pande M. Innovative polymer-based therapeutics targeting inflammation for responsive drug delivery in disease treatment. Inflammopharmacology. 2025 Oct 13:1-7.
41. Prajapati RN, Bhushan B, Singh K, Chopra H, Kumar S, Agrawal M, Pathak D, Chanchal DK, Laxmikant. Recent advances in pharmaceutical design: unleashing the potential of novel therapeutics. Current Pharmaceutical Biotechnology. 2024 Dec 1;25(16):2060-77.
42. Dey S, Hassan S, Pandey RK. Nanomedicine in targeted drug delivery: precision therapeutics for personalized medicine. InNanomedicine: Innovations, Applications, and Breakthroughs in the Quest for Health and Medicine's Future 2024 Dec 10 (pp. 179-231). Cham: Springer Nature Switzerland.
43. Ding M, Zhao W, Song LJ, Luan SF. Stimuli-responsive nanocarriers for bacterial biofilm treatment. Rare Metals. 2022 Feb;41(2):482-98.
44. Zhang B, Lu D, Duan H. Recent advances in responsive antibacterial materials: design and application scenarios. Biomaterials Science. 2023;11(2):356-79.
45. Wu JM, Liu Y, Han HY, Song ZY. Recent advances in endogenous and exogenous stimuli-responsive nanoplatforms for bacterial infection treatment. Biomed. Eng. Commun. 2023;2(1):2-3.
46. Ricotti L, Cafarelli A, Iacovacci V, Vannozzi L, Menciassi A. Advanced micro-nano-bio systems for future targeted therapies. Current Nanoscience. 2015 Apr 1;11(2):144-60.
47. Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. Journal of Nanobiotechnology. 2022 Aug 31;20(1):395.
48. Saifi MA, Khan W, Godugu C. Cytotoxicity of nanomaterials: Using nanotoxicology to address the safety concerns of nanoparticles. Pharmaceutical nanotechnology. 2018 Mar 1;6(1):3-16.
49. Saini V, Chakraborty T, Jain A, Chaudhary J, Saini V “Comparative Study of Resins in the Formulation of Taste Masked Suspension of Erythromycin” Int. J.Pharm. Sci. Rev. Res.,2013,  22(1): 257-263
50. Shahiwala A. Advancing drug delivery research: sustainable strategies for innovation and translation. Drug Delivery and Translational Research. 2025 May;15(5):1513-24.
51. Mahyad B, Janfaza S, Hosseini ES. Bio-nano hybrid materials based on bacteriorhodopsin: potential applications and future strategies. Advances in colloid and interface science. 2015 Nov 1;225:194-202.
52. Barbinta-Patrascu ME, Badea N, Pirvu C, Bacalum M, Ungureanu C, Nadejde PL, Ion C, Rau I. Multifunctional soft hybrid bio-platforms based on nano-silver and natural compounds. Materials Science and Engineering: C. 2016 Dec 1;69:922-32.
53. Shahcheraghi N, Golchin H, Sadri Z, Tabari Y, Borhanifar F, Makani S. Nano-biotechnology, an applicable approach for sustainable future. 3 Biotech. 2022 Mar;12(3):65.
54. Mohanty D, Suar M, Panda SK. Nanotechnological interventions in bacteriocin formulations–advances, and scope for challenging food spoilage bacteria and drug-resistant foodborne pathogens. Critical Reviews in Food Science and Nutrition. 2025 Feb 25;65(6):1126-43.
55. Sidhu PK, Nehra K. Bacteriocin-nanoconjugates as emerging compounds for enhancing antimicrobial activity of bacteriocins. Journal of King Saud University-Science. 2019 Oct 1;31(4):758-67.
56. Chakraborty T, Saini V, Sharma S, Kaur B, Dhingra G “Antifungal gel; for different routes of administration and different drug delivery system” International Journal of Biopharmaceutics, 2014, 5(3): 230-240
57. Lin Z, Gao W, Hu H, Ma K, He B, Dai W, Wang X, Wang J, Zhang X, Zhang Q. Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals: High drug-loading, sustained drug release and extended local retention guaranteeing better efficacy and lower toxicity. Journal of Controlled Release. 2014 Jan 28;174:161-70.
58. Li J, Cheung WH, Chow SK, Ip M, Leung SY, Wong RM. Current therapeutic interventions combating biofilm-related infections in orthopaedics: a systematic review of in vivo animal studies. Bone & Joint Research. 2022 Oct 4;11(10):700-14.
59. Borgert CJ, Fuentes C, Burgoon LD. Principles of dose-setting in toxicology studies: the importance of kinetics for ensuring human safety. Archives of Toxicology. 2021 Dec;95(12):3651-64.
60. Chinemerem Nwobodo D, Ugwu MC, Oliseloke Anie C, Al‐Ouqaili MT, Chinedu Ikem J, Victor Chigozie U, Saki M. Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. Journal of clinical laboratory analysis. 2022 Sep;36(9):e24655.
61. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C. Antibiotic resistance—the need for global solutions. The Lancet infectious diseases. 2013 Dec 1;13(12):1057-98.